AUTHORS
Ekrem Turk, MD, Neha Gutta, MD2, Colin Slaymake, MD3, Ling Zhang, MD4, Micayla Sloat5, Shreeya Mathur6, Julia Cooper, MS, LGC7, Jayanshu Jain, MD8, Rory Shallis I, MD9, Onyee Chan, MD10, Samuel Benjamin Reynolds, MD11, Alison Walker, MD12, Seongseok Yun, MD, PhD13, Christopher Ryder, MD PhD14, Hailing Zhang, MD15, Jeffrey Lancet, MD16, David Sallman, MD17, Rami Komrokji, MD18, Eric Padron, MD19, Andrew T Kuykendall, MD20, Uma Borate, MBBS, MSc21, Alexander Bick, MD, PhD22, Ashwin Kishtagari, MBBS, MSCI23, Zhuoer Xie, MD,MS24
AFFILIATIONS
1 H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
2 University of South Florida, Tampa, Florida, United States
3 Vanderbilt University Medical Center, Nashville, Tennessee, United States
4 H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
5 Vanderbilt University Medical Center, Nashville, Tennessee, United States
6 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
7 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
8 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
9 H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
10 H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
11 H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
12 H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
13 H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
14 H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
15 H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
16 H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
17 H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
18 H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
19 H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
20 H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
21 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
22 Vanderbilt University Medical Center, Nashville, Tennessee, United States
23 Vanderbilt University Medical Center, Nashville, Tennessee, United States
24 H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
ABSTRACT
Introduction:
JAK2 V617F-mutant clonal hematopoiesis (CH) is rare but carries the highest thrombotic risk among recurrent CH genotypes, with an approximately fourfold increased risk of venous thromboembolism (VTE) and potential evolution to hematologic malignancy. However, large-scale studies integrating clone size, co-mutations, bone marrow findings, and longitudinal outcomes remain limited, particularly for clones below the conventional 2% variant allele frequency (VAF) threshold. We therefore characterized the molecular landscape, thrombotic events, and hematologic progression in a multi-institutional, clinically ascertained cohort of patients with JAK2-mutant CH, including clones with VAF below 2%.
Methods:
We retrospectively analyzed 45 patients in a multi-institutional JAK2-mutant CH database. The primary endpoint was qualifying thrombosis and its association with continuous JAK2 VAF. Secondary analyses evaluated venous and arterial events, event timing, post-index incidence, VAF thresholds of 2% and 5%, and hematologic progression to diagnostic myeloid neoplasm. Exploratory analyses compared demographics, cardiovascular risk factors, complete blood counts (CBC), lipid profiles, body mass index (BMI), medications, co-mutations, and marrow findings by thrombosis status and descriptively compared progressors with non-progressors. Continuous variables were reported as median [interquartile range] and compared by Wilcoxon rank-sum; categorical variables by Fisher's exact tests. Incidence was reported per 100 person-years.
Results:
Among 45 patients, median age was 66.0 years [57.1–74.0]; 64.4% (29) were female; 97.8% (44) were White; 35.6% (16) were ever smokers; and median BMI was 27.4 kg/m² [23.7–32.9]. Low-dose aspirin was used by 66.7% (30) of patients, and statins by 51% (23).
JAK2 V617F was presented in 86.7% (39/45), the noncanonical M532I in 2.2% (1/45), and unspecified JAK2 variants in 11.1% (5/45). Among 38 patients with numeric VAF, the median VAF was 2.0% [0.9–4.5]; 47.4% (18) had VAF <2%, 52.6% (20) had VAF ≥2%, and 23.7% (9) had VAF ≥5%.
Co-mutations were documented in 51.1% (23) of patients. The dominant co-mutations were TET2 and DNMT3A, each identified in 8 patients (17.8% of the full cohort). Baseline CBC values did not differ significantly between patients with and without thrombosis. Marrow evaluation in 32 patients showed megakaryocytic atypia/dysplasia in 6 and hyperplasia in 5, without definite syncytial clustering. Progressors had higher median platelet counts than non-progressors (427 versus 242 ×10⁹/L), although only four patients progressed.
Thrombosis occurred in 33.3% of patients (15): 20.0% (9 venous) and 22.2% (10 arterial). Most events occurred before or at index testing (n=11), reflecting thrombosis-triggered clinical ascertainment. Among 30 patients without prior thrombosis, 2 developed a first post-index event over 58.8 person-years, yielding an incidence of 3.4 per 100 person-years (95% CI, 0.41–12.28; median time to event was 2.15 years). Thrombosis was not associated with continuous VAF (OR per 1-percentage-point increase, 0.83; 95% CI, 0.60–1.16; P=.275), VAF cutoffs of 2% or 5% (P=.724 and P=.237), co-mutation status (P=.758), TET2 (P=1.00), or DNMT3A (P=.236). In an exploratory analysis of 22 patients, median HDL cholesterol was lower among patients with thrombosis than among those without thrombosis (42.5 vs 56.0 mg/dL; P=.019)
Four patients (8.9%), all with V617F, progressed after a median of 1.98 years [1.72–2.20]: 2 to essential thrombocythemia, 1 to polycythemia vera, and 1 to chronic myelomonocytic leukemia. Median baseline VAF was 1.8% in progressors versus 2.0% in non-progressors, whereas platelet counts were 427 versus 242 ×10⁹/L.
Conclusions:
In this multi-institutional cohort, JAK2-mutant CH confers substantial thrombotic risk even at sub-2% VAF levels, challenging conventional 2% VAF thresholds for clinical risk stratification. These clinical observations align with mechanistic models proving that low clone burdens are sufficient to trigger prothrombotic cascades. Hematologic progression occurred at modest VAF levels and was accompanied by numerically higher baseline platelet counts. Lower HDL levels reflect cardiovascular/lipid co-risk in somatic JAK2-mutant CH states.
DISCLOSURES
Ekrem Turk, MD: No relevant conflicts of interest to declare.